Tevogen Bio Holdings (TVGN) Income from Continuing Operations (2023 - 2026)
Tevogen Bio Holdings (TVGN) reported Income from Continuing Operations of 5400920.0 for Q1 2026, up 47.97% on a YoY basis from 3649945.59 in Q1 2025, and down 17.15% quarter-over-quarter from 4610201.0 in Q4 2025.
Tevogen Bio Holdings (TVGN) Income from Continuing Operations (2023 - 2026) Analysis & Trends
Tevogen Bio Holdings has reported Income from Continuing Operations for 4 years, with the latest figure at 5400920.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 47.97% year-over-year to 5400920.0; the trailing twelve-month figure through Mar 2026 stood at 21185088.0 (up 38.52% YoY), and the FY2025 full-year result was 26140515.0, up 51.37% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 5400920.0, down from 4610201.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 2184466.0 in Q2 2023, with the low at 29672510.0 in Q1 2024.
- Historically, Income from Continuing Operations has averaged 7312617.46 across 4 years, with a median of 5444536.0 in 2025.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations sank 1035.45% — and 2025, when it jumped 65.02%.
- Tevogen Bio Holdings' Income from Continuing Operations stood at 2326794.0 in 2023, then sank by 303.09% to 9379008.0 in 2024, then surged by 50.85% to 4610201.0 in 2025, then slipped by 17.15% to 5400920.0 in 2026.
- The last three Income from Continuing Operations figures came in at 5400920.0 (Q1 2026), 4610201.0 (Q4 2025), and 5729431.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -56.48 Mn |
| 10 | Tevogen Bio Holdings | 182.04 Mn | 181.35 Mn | - | -5.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.40 Mn |
| Dec 31, 2025 | -4.61 Mn |
| Sep 30, 2025 | -5.73 Mn |
| Jun 30, 2025 | -5.44 Mn |
| Mar 31, 2025 | -10.38 Mn |
| Dec 31, 2024 | -9.38 Mn |
| Sep 30, 2024 | -6.10 Mn |
| Jun 30, 2024 | -8.60 Mn |
| Mar 31, 2024 | -29.67 Mn |
| Dec 31, 2023 | -2.33 Mn |
| Sep 30, 2023 | -2.62 Mn |
| Jun 30, 2023 | -2.18 Mn |
| Mar 31, 2023 | -2.61 Mn |